Pirfenidone in Idiopathic Pulmonary Fibrosis "rECAP-itulating Safety into the Real World"

Respiration

Volumn 94, Issue 5, 2017, Pages 405-407

  Tzouvelekis, Argyris ^a,b   Bouros, Evangelos ^a   Tzilas, Vasilios ^a   Bouros, Demosthenes ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Amyloidosis; Common variable immunodeficiency; Humoral immunity; IgG4; Light chain deposition disease; Lung

Indexed keywords

PIRFENIDONE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

CLINICAL PRACTICE; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FIBROSING ALVEOLITIS; HUMAN; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; DRUG EFFECTS; VITAL CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; VITAL CAPACITY;

EID: 85029007930     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000480299     Document Type: Review

References (15)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Bouros D, Tzouvelekis A: Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med 2014; 2: 17-19.
3. Tzouvelekis A, Tzilas V, Papiris S, Aidinis V, Bouros D: Diagnostic and prognostic challenges in idiopathic pulmonary fibrosis: a patient "Q and A" approach. Pulm Pharmacol Ther 2017; 42: 21-24.
4. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A: Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008; 590: 400-408.
5. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
6. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
7. Bouros D: Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377: 1727-1729.
8. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR: Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017, Epub ahead of print.
9. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr: Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
10. Costabel U, Albera C, Lancaster LH, Lin C-Y, Hormel P, Hulter HN, Noble PW: An openlabel study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration 2017;94:408-415.
11. Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM: Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198-205.
12. Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, Guenther A, Albera C: Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 191: 110-113.
13. Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S, Warth A, Herth FJ, Kreuter M: Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a german tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207.
14. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
15. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW: Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016; 3:e000105.